Table 3.

Comparison of the estimated association of induction treatments on acute rejection at 1 year using multivariable logistic regression models

Induction TypeAcute Rejection Rate within 1 yr, %ORa95% CIP Value
Steroid
 Logistic regressiona
  IL2-RA12.41
  r-ATG9.10.720.65 to 0.79<0.001
  Alemtuzumab11.60.930.76 to 1.120.44
  No induction13.30.990.89 to 1.110.91
 PS–weighted logistic regressionb
  IL2-RA12.41
  r-ATG9.10.680.62 to 0.74<0.001
  Alemtuzumab11.60.900.74 to 1.100.32
  No induction13.30.900.81 to 1.010.06
No steroid
 Logistic regressiona
  IL2-RA11.11
  r-ATG9.60.870.68 to 1.120.29
  Alemtuzumab9.10.710.54 to 0.940.02
 PS–weighted logistic regressionb
  IL2-RA11.11
  r-ATG9.60.800.60 to 1.000.05
  Alemtuzumab9.10.680.53 to 0.880.004
  • OR, odds ratio; 95% CI, 95% confidence interval; IL2-RA, IL-2 receptor antagonist; r-ATG, rabbit antithymocyte globulin; PS, propensity score.

  • a Adjusted for donor factors (sex and kidney donor profile index), recipient factors (age, sex, race, diabetes status, cardiovascular disease, panel reactive antibody, retransplant status, and dialysis exposure), transplant factors (cold ischemia time, donor-to-recipient weight ratio, HLA mismatch, and transplant year), transplant center, and the Organ Procurement and Transplantation Network region.

  • b PS weighted and adjusted for transplant center and the Organ Procurement and Transplantation Network region.